Lantern Pharma (LTRN) Reports Q2 Loss of $0.31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Colliers Securities Starts Lantern Pharma Inc. (LTRN) at Buy
July 28, 2020 7:42 AM EDTColliers Securities initiates coverage on Lantern Pharma Inc. (NASDAQ: LTRN) with a Buy rating and a price target of $24.00.
For an analyst ratings summary and ratings history on Lantern Pharma Inc.... More
